Study	Reason for exclusion
Allen 2007	Allocation: not randomised (post‐hoc analysis of pooled data from 3 RCT's).
Andrezina 2006	Allocation: randomised. Participants: schizophrenia. Interventions: sub‐population post‐hoc analysis of a previously reported RCT which has been included in this review.
Argo 2004	Allocation: not randomised.
Carson 2002	Allocation: not randomised.
Carson 2004	Allocation: not randomised (naturalistic study).
Casey 2002	Allocation: randomised. Participants: schizophrenia or schizoaffective disorder. Interventions: aripiprazole at different switching regimens as interventions ‐ no other comparator drug.
Jung 2007	Allocation: not described. Participants: schizophrenia. Interventions: haloperidol with adjunctive aripiprazole compared with haloperidol with adjunctive placebo.
Kelemen 2006	Allocation: not described. Participants: schizophrenia. Interventions: allocation to typical and atypical drugs ‐ no data available for individual drugs.
Kim 2006	Allocation: quasi‐randomisation.
Kim 2007	Allocation: randomisation. Participants: schizophrenia or schizoaffective disorder. Interventions: switch from existing antipsychotics to aripiprazole and other antipsychotics. Aripiprazole not compared with any specific antipsychotic.
Petrie 1997	Allocation: not randomised, review.
Shim 2006	Allocation: not described. Participants: schizophrenia, with hyperprolactinaemia after taking haloperidol. Interventions: aripiprazole versus placebo as adjunctive treatment for people receiving haloperidol.
Swanson 2006	Allocation: not randomised.
Talbott 2007	Allocation: not randomised (post‐hoc analysis of pooled data from 3 RCT's).
Wu 2005	Allocation: quasi‐randomisation.
Xia 2005	Allocation: randomised. Participants: schizophrenia. Interventions: allocation to aripiprazole and chlorpromazine. Outcomes: no usable data.